September 2019

 

In this Issue

Paclitaxel In PAD

Applying What We've Learned Since the Meta-Analysis

Issue

Supplement

Guest Chief Medical Editors’ Page

After the Meta-Analysis…

By Sabine Steiner, MD; and Ramon L. Varcoe, MBBS, MS, FRACS, PhD

COVER STORIES

Nine Months Later… An Interview With Konstantinos Katsanos, MD

Dr. Katsanos’s thoughts regarding the vascular community’s reaction to his group’s meta-analysis, the potential influence of follow-up and adjudication variables, non-SFA applications, and what comes next.

With Konstantinos Katsanos, MSc, MD, PhD, EBIR

Panel Discussion: Exploring the Paclitaxel Safety Signal

Experts discuss considerations in trial design, adjudication, and paths forward.

With Marianne Brodmann, MD; William Gray, MD; Peter A. Schneider, MD; Ramon L. Varcoe, MBBS, MS, FRACS, PhD; and Thomas Zeller, MD, PhD

Paclitaxel Post-Panel: FDA Discusses What’s Next From a Regulatory Perspective

An interview with representatives from the FDA Center for Devices and Radiological Health on the key updates to the letter to health care providers, lessons learned for future trials and follow-up protocols, and additional plans for monitoring in the future.

With Eleni Whatley, PhD; and Andrew Farb, MD

Ask the Experts: How Do You Define ‘High Risk for Restenosis’?

With Gary M. Ansel, MD; Herbert D. Aronow, MD, MPH, FACC, FSCAI, FSVM; Marianne Brodmann, MD; Koen Deloose, MD; Andrew Holden, MBChB, FRANZCR, EBIR; John H. Rundback, MD; and Peter A. Schneider, MD

Understanding the Paclitaxel Dose Effect

Answers to key questions about the paclitaxel controversy, including why the dose-response effect discussion is important and the impact of improved patient-level data collection.

By Andrew Holden, MBChB, FRANZCR, EBIR

Real-World Data Collection Regarding Paclitaxel Treatment

An overview of why real-world data are pertinent to the safety assessment of paclitaxel-coated devices, with separate summaries of the projects investigating the late mortality signal via real-world data analyses.

By Anna Krawisz, MD; and Eric A. Secemsky, MD

Medicare Database Project

By Anna Krawisz, MD, and Eric A. Secemsky, MD

Optum Database Project

By Robert Yeh, MD, and Eric A. Secemsky, MD

The Natural History of Intermittent Claudication

Considering atypical presentations of symptomatic peripheral artery disease and the associated major adverse events.

By Amit N. Keswani, MD; and Joshua A. Beckman, MD

A Retrospective Look at Paclitaxel Use in the Coronary Arteries

A review of the safety and efficacy profile of paclitaxel treatment in patients with coronary artery disease.

By Mark K. Tuttle, MD; and Jeffrey J. Popma, MD

Lesion-Specific SFA Device Selection

Key questions to consider for accurate diagnoses and tailored treatment decisions.

By Koen Deloose, MD

Pipeline Report: A Look at Next-Generation SFA Technologies

A review of the recent advances in lesion crossing, atherectomy, vessel preparation, and drug delivery technologies.

By Sabine Steiner, MD; and Andrej Schmidt, MD

FEATURED TECHNOLOGY

Sponsored by Ra Medical Systems, Inc.

Case Report: Severe Common Femoral Artery Disease and Failed Femoropopliteal Artery Graft: Amputation Avoided Through Use of DABRA Excimer Laser in an OBL Setting

By Mubashar Choudry, MD, FACC; Rashid A. Chotani, MD, MPH, FRCPH; James Rothstein, MD; and Amit Kumar Rajvanshi, MD
Sponsored by Veryan Medical Ltd.

Swirling Flow®: Nature’s Ideal Alternative to Drug Elution

How swirling flow induced by the BioMimics 3D stent provides a drug-free solution for limiting restenosis and reducing the need for revascularization.

By Peter Gaines, MD, MRCP, FRCR

EUROPEAN FEATURED TECHNOLOGY

Sponsored by Penumbra, Inc.

Indigo System for Peripheral Arterial Clot Management

With Gianmarco de Donato, MD; Theodosios Bisdas, MD; Costantino Del Giudice, MD, PhD; Katharine Lewis, MBBS, FRCR, FHEA; Mario Corona, MD; Pierleone Lucatelli, MD; and Martin Schröder, MD

MEDICAL AFFAIRS CORNER

Sponsored by Medtronic

IN.PACT™ Admiral™ DCB: Safety and Effectiveness in Treating Complex Lesions

Weighing the risks and benefits when treating complex lesions in the femoropopliteal vascular bed.

By Gary M. Ansel, MD, FACC

DEPARTMENTS

European Innovations

An Interview With Patrick Chong, MBBS, FRCS (Eng), FRCS (Gen Surg)

Mr. Chong discusses the current status of the BASIL-3 trial, NICE AAA guidance, and his advice for engaging in online clinical discussion platforms.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.